V-9402 Vandetanib, Free Base, >99%

Related Terms : [Caprelsa] [Zactima] [ZD6474]

  • Size
  • US $
  • £
  • ¥
  • 25 mg
  • 44
  • 39
  • 32
  • 4,500
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 56
  • 50
  • 41
  • 5,800
  • Add to Cart Qty:
  • In stock
  • 100 mg
  • 87
  • 78
  • 64
  • 8,900
  • Add to Cart Qty:
  • In stock
  • 200 mg
  • 142
  • 127
  • 105
  • 14,600
  • Add to Cart Qty:
  • In stock
  • 250 mg
  • 172
  • 154
  • 127
  • 17,700
  • Add to Cart Qty:
  • In stock
  • 500 mg
  • 262
  • 235
  • 194
  • 26,900
  • Add to Cart Qty:
  • In stock
  • 1 g
  • 475
  • 426
  • 352
  • 48,800
  • Add to Cart Qty:
  • In stock
  • 2 g
  • 854
  • 766
  • 634
  • 87,800
  • Add to Cart Qty:
  • In stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 475.35
  • C22H24BrFN4O2
  • [443913-73-3]
  • M.I. 14: 10249

Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 30 mg/mL; soluble in ethanol at 10 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.

  • Vandetanib inhibits VEGFR-dependent tumor angiogenesis and EGFR- and RET-dependent tumor cell proliferation and survival. Herbst, R.S., et al. "Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis." Expert Opin. Investig. Drugs 16: 239-249 (2007).
  • The IC50 values for vandetanib in HT-29 and LoVo cells are 10-80 µM and 3.5-16 µM, respectively, when the exposure times are from 3 days to 18 hours. Azzariti, A., et al. "Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects." World J. Gastroenterol. 12: 5140-5147 (2006).
  • Vandetanib is a potent, orally-active inhibitor of kinase insert domain-containing receptor [KDR/vascular endothelial growth factor receptor (VEGFR) 2] tyrosine kinase activity (IC50 = 40 nM). This compound also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC50 = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC50 = 500 nM) but shows selectivity relating to a range of other tyrosine and serine-threonine kinases. The activity of vandetanib against KDR tyrosine kinase may explain its potent inhibition of vascular endothelial growth factor A-stimulated human umbilical vein endothelial cell proliferation in vitro (IC50 = 60 nM). Wedge S.R., et al. "ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling, Angiogenesis, and Tumor Growth following Oral Administration." Cancer Res. 62: 4645-4655 (2002).
  • Vandetanib dose-dependently inhibited EGFR tyrosine kinase activity with IC50 of 0.25 µM. Vandetanib also inhibited colony formation of seven cancer cell lines in soft agar with IC50's ranging between 0.5 and 1 µM. Ciardiello F., et al. "Antitumor Effects of ZD6474, a Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, with Additional Activity against Epidermal Growth Factor Receptor Tyrosine Kinase." Clin. Cancer Res. 9: 1546-1556 (2003).
  • Vandetanib is the active ingredient in the drug sold under the trade name Caprelsa® and has been approved in at least one country for treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer. NOTE: The vandetanib sold by LC Laboratories is NOT Caprelsa®, and is NOT for human use.
  • Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
322